SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
Annual Report pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
For the Year Ended December 31, 1996
Commission File Number 0-24496
GEN/Rx, Inc.
(Name of Business)
NEW YORK 11-2728666
(State Or Other Jurisdiction Of (I.R.S. Employer
Incorporation Or Organization) Identification No.)
600 Woodmere Boulevard, Woodmere, New York 11598
(Address Of Principal Executive Office) (Zip Code)
Registrant's telephone number, including area code: (516) 569-3800
Securities registered pursuant to Section 12(b) of the Exchange Act of 1934:
Title of class Name of each exchange on which registered
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.004 par value
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding twelve months (or for such shorter period that the
registrant was required to file such reports) and (2) has been subject to such
filing requirements for the past 90 days: Yes |_| No |X|
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. |X|
$5,525
Aggregate Market Value of the voting and non-voting common stock held by
non-affiliates of the registrant as of May 22, 2003. The last date on which a
sale of common stock was reported in the over-the-counter market was
November 15, 2001
20,878,711
Number of shares of common stock outstanding as of May 22, 2003
PORTIONS OF THE FOLLOWING DOCUMENTS HAVE BEEN INCORPORATED BY
REFERENCE INTO THIS ANNUAL REPORT ON FORM 10-K:
IDENTITY OF DOCUMENTS PARTS OF FORM 10-K INTO
WHICH DOCUMENT IS
INCORPORATED
None
10-K
PART I
ITEM 1. BUSINESS
General
GEN/Rx, Inc. ("GEN/Rx" or the "Company") effectively ceased operations
June 30, 1996. Prior to June 30, 1996, GEN/Rx was a holding company which,
through its subsidiaries, was in the business of developing, manufacturing and
distributing generic injectable drugs. GEN/Rx had three wholly-owned
subsidiaries: AUSA, Inc. ("AUSA"), which was sold to the Company's major
shareholder, Apotex Corp. (formerly known as Apotex USA, Inc.) ("Apotex"), in
June 1996; American Veterinary Products, Inc. ("AVP"), which discontinued
operations in December 1995; and Collins Laboratories, Inc. ("Collins"), which
has been inactive since its inception. The Company experienced significant
operating losses from its inception in July 1994, resulting in a deficit equity
position.
On June 27, 2002, the Company was dissolved by proclamation of the
secretary of state of the state of New York for failure to file franchise tax
reports or pay franchise taxes. The Company is currently seeking reinstatement.
See "Legal Proceedings."
Unless the context requires otherwise, references in this Annual Report to
the "Company" shall be deemed to include, collectively, GEN/Rx and all of its
subsidiaries.
History
Business Combination
On April 13, 1995, the Company's newly formed wholly-owned subsidiary,
GEN/Rx Acquisition Subsidiary, Inc., merged with and into AUSA (the "Merger").
Pursuant to the Merger, the Company acquired all the assets of AUSA, a company
engaged in the distribution of injectable drugs.
Prior to the Merger, AUSA was a subsidiary of Apotex. As part of the
Merger transaction, the Company issued to Apotex 15,353,840 shares of its Common
Stock, as a result of which Apotex became the owner of approximately 74% of the
outstanding Common Stock of the Company. In addition, the Company issued
warrants to various individuals to purchase 270,000 shares of common stock of
GEN/Rx for $1.50 per share. See "Notes to Financial Statements--Note C. Business
Combination."
Loan Agreement
1
In connection with the Merger, pursuant to a loan agreement dated April
13, 1995, between the Company and Apotex (the "Loan Agreement"), Apotex lent the
Company $500,000 represented by a Term Note dated April 13, 1995, and $2,000,000
represented by a revolving line of credit note dated April 13, 1995. See
"Default of Loan Covenants" below. The notes bore interest at 1% over prime and
had a maturity date of April 13, 1998. These notes were secured by all of the
assets of the Company. As additional consideration for the loans, Apotex
received warrants exercisable at $1.00 per share to purchase shares of the
Company's common stock in an amount equal to one share for each dollar advanced
pursuant to the Loan Agreement. The warrants had a term of three years. At
December 31, 1995, the Company had borrowed the full $2,500,000 pursuant to this
Loan Agreement.
Default of Loan Covenants
On November 29, 1995, the Company entered into an agreement with Apotex to
amend the Loan Agreement. As amended, the Loan Agreement permitted Apotex, in
its discretion, to advance sums in excess of the $2,500,000 original loan
amount, that were due December 22, 1995, but otherwise were treated as if they
had been advanced pursuant to the Loan Agreement. The Company requested
additional advances and Apotex advanced the Company approximately $325,000
through December 31, 1995. The Company agreed that failure to repay the amounts
when due would constitute a default under the Loan Agreement. The Company also
issued to Apotex a warrant to purchase an additional 813,783 shares of the
Company's common stock at an exercise price of $.75 per share in connection with
the amendment. The warrants had a term of three years.
At December 31, 1995, the Company was indebted to Apotex for an aggregate
of $3,563,000, including $447,000 of accounts payable converted to notes
pursuant to the amendment to the Loan Agreement. The Company's failure to pay
the amounts due December 22, 1995 constituted an Event of Default under the Loan
Agreement, as amended, and Apotex by a letter dated January 2, 1996, accelerated
the entire amount of indebtedness of the Company and its subsidiaries, which
were jointly and severally liable for the debt. As a result of the acceleration,
on January 5, 1996, the Company turned over to Apotex all of the collateral
securing the loans under the amended Loan Agreement, including AVP's Ft. Collins
plant. The Company continued to receive additional advances from Apotex in 1996
in the aggregate amount of $862,000. At June 30, 1996, the Company was indebted
to Apotex for an aggregate of $5,296,659 (before the sale of AUSA) including
$747,423 of accounts payable converted to notes pursuant to the Loan Agreement,
as amended.
On January 4, 1996, Apotex sought and received the appointment of a
receiver for AVP's Ft. Collins plant in a proceeding in Larimer County,
Colorado. See "Discontinued Operations of AVP" below. The order permitted the
receiver to exercise control over AVP's bank accounts, accounts receivable and
inventory. As a result of the November 29, 1995 amendment to the Loan Agreement
and the appointment of a receiver, AVP stopped receiving any cash proceeds from
the Apotex loans. AVP subsequently discontinued operations. See "Discontinued
Operations of AVP" below. In addition, pursuant to the Loan Agreement, as
amended, accounts receivable of AUSA were assigned to Apotex and collections
thereof were deposited into the bank accounts of Apotex. Apotex subsequently
purchased all of the outstanding capital stock of AUSA on July 1, 1996. See
"Sale of AUSA" below.
2
Sale of AUSA
In February 1996, in light of the Company's losses, the Company retained
the services of the investment banking firm Hill Thompson Capital Markets, Inc.,
to assist management in its efforts to identify steps and strategies to reduce
losses, generate returns on the Company's assets and maximize shareholder
values. Hill Thompson recommended the sale of AUSA, identified potential
purchasers for AUSA, prepared a confidential descriptive memorandum and sought
to solicit interest in AUSA on behalf of the Company. Hill Thompson was not
successful in soliciting any interested parties.
The Company held an auction on June 28, 1996 to sell the 100 shares of
AUSA common stock outstanding. All of such shares were subject to a perfected
security interest in favor of Apotex. The auction was held at Hill Thompson's
office at 437 Madison Avenue in New York City and the minimum price for the AUSA
shares was $1,000,000. At the auction, Apotex bid $1,000,000 for the shares of
AUSA. Apotex was the only bidder at the auction. The Company and Apotex
consummated the purchase with an effective date of July 1, 1996, promptly after
the auction. Apotex's acquisition of AUSA from the Company resulted in a
reduction of the Company's indebtedness in favor of Apotex by $1 million. At
September 30, 1996, after the sale of AUSA to Apotex, the Company indebtedness
to Apotex equaled approximately $4,400,000, all of which was due and payable.
Discontinued Operations of AVP
In connection with an inspection by the U.S. Food and Drug Administration
("FDA") of AVP's manufacturing facility from October 1994 through May 1995, AVP
received a "warning letter" from the Denver District Office of the FDA setting
forth certain alleged deviations from current good manufacturing practice
regulations ("GMP"s) and alleged violations of related provisions of the Federal
Food, Drug and Cosmetic Act.
In June 1995, following new management's investigation of the matters set
forth in the warning letter, management suspended indefinitely the manufacture
of products. In December 1995, management decided to discontinue the operations
of AVP, because it determined that the time and financial commitment required to
rehabilitate AVP's operations would be too great for the Company to pursue. In
connection with management's decision to discontinue the operations of AVP, the
Company laid-off substantially all of its personnel at this facility and
recorded a provision of $5,646,000 in its 1995 financial statements. Results of
operations of AVP and AUSA are shown separately as discontinued operations on
the consolidated statement of operations. See "Notes to Financial Statements -
Note B. Discontinued Operations."
In January 1996, the Larimer County (Colorado) District Court appointed a
receiver for AVP, including the Ft. Collins plant. The receiver liquidated
approximately all of AVP's assets at its three locations in or near Ft. Collins,
Colorado, for proceeds aggregating approximately $670,000. The receiver used the
proceeds for disposal of hazardous and other wastes at the Ft. Collins plant and
for continued care of AVP's inventory and other payroll and non-payroll related
expenses. Upon final order of the court dated September 22, 1998, directing
final payments from the court supervised account, all remaining cash in the
account, amounting to approximately $40,000, was paid to Apotex. In addition, on
January 13, 1997, the Ft. Collins
3
plant was conveyed to Apotex by deed in lieu of foreclosure proceedings. In May
1997, Apotex sold the Ft. Collins plant to an unrelated third party for $475,000
consisting of $365,000 in cash and a promissory note in the amount of $100,000,
bearing interest at 10% per annum, payable monthly, which note was paid to
Apotex in full on the one-year anniversary of such sale. Nonetheless, even after
Apotex's receipt of such proceeds from the liquidation of the Company's assets
and sale of the Ft. Collins property, the Company remained indebted to Apotex in
the amount of approximately $4,400,000 at June 30, 1997.
Financial Statements Presentation
With respect to the Company's financial information set forth in this
Annual Report relating to the year ended December 31, 1996, the financial
statements are presented on a going concern basis for all periods through June
30, 1996, and on a liquidation basis subsequent to June 30, 1996. All of the
operations of AVP and AUSA are treated as discontinued operations. Substantially
all of the Company's revenue for the period ended June 30, 1996 were derived
from sales of AUSA products.
Present Lack of Operations
The Company has not conducted any business operations since the sale of
AUSA on June 30, 1996. All activities of the Company after such date related
principally to the liquidation of the AVP assets by the receiver and the sale of
the Ft. Collins plant.
The Company does not have any employees or executive officers, other than
Jack Margareten, who serves as part-time Acting President and Chief Financial
Officer. The Company's Board of Directors has four seats, three of which are
vacant. Jack Margareten is the sole director of the Company. Mr. Margareten was
appointed sole director and elected as Acting President of the Company and its
subsidiaries in May 1997 after then-President, Chief Executive Officer and sole
director Jack M. Schramm resigned from such positions. Mr. Schramm also served
as President of both Apotex, which owns approximately 74% of the Company, and
AUSA, a former subsidiary of the Company acquired by Apotex June 30, 1996. Mr.
Margareten, who prior to May 1997 served as Chief Financial Officer of the
Company and Apotex, also replaced Mr. Schramm as Acting President of Apotex in
May 1997. As of June 30, 1996, AUSA had 16 full-time employees, of which seven
were engaged in product development, five were involved with sales and marketing
and four were devoted to finance and administration. On June 30, 1996, the
Company sold its interest in AUSA to Apotex. AVP did not conduct operations or
have any employees in 1996.
Prior to July 1, 1996, the Company's executive offices were located at
1776 Broadway Suite 1900, New York, New York 10019. All business operations have
ceased and the Company does not lease or own any real property. For purposes of
this Annual Report, the Company's office is c/o Jack Margareten, 600 Woodmere
Boulevard, Woodmere, New York 11598.
After the Company was placed in receivership and AUSA was sold to Apotex,
Exchange Act reports relating to the Company were no longer filed with the
Securities and Exchange Commission. Apotex, the Company's principal shareholder,
is currently considering various business alternatives relating to the Company,
including, but not limited to, commencing
4
new business operations, dissolving the Company or seeking an interested
investor for a sale of its stock holdings in the Company. Accordingly, the
Company is filing presently this Annual Report for the fiscal year ended
December 31, 1996, and subsequent Exchange Act reports in order to bring the
Company's reporting up to date. There can be no assurance that Apotex will
pursue one or more of these or other alternatives relating to the Company, or,
if it does, that any of such pursuits will be successful. See "Legal
Proceedings."
ITEM 2. PROPERTIES
The Company does not own or lease any real property.
Prior to June 30, 1996, the Company had executive offices occupying a
3,000 square foot office in New York City. The Company had an informal agreement
with Apotex as sublessor of such space.
Prior to December 1995, AVP's manufacturing facility occupied an 11,000
square foot facility on approximately 3 acres of land in Ft. Collins Colorado.
See "Business - Discontinued Operations of AVP."
Prior to the June 30, 1996 sale of AUSA to Apotex, the Company leased a
7,000 square foot facility in Lake Forest, Illinois for AUSA's human injectable
product development operations.
ITEM 3. LEGAL PROCEEDINGS
On January 4, 1996, in connection with the default by the Company on the
Loan Agreement, as amended (See "Business-Default of Loan Covenants"), Apotex
sought and received the appointment of a receiver for AVP's Ft. Collins plant in
a proceeding in Larimer County, Colorado. The Court's order permitted the
receiver to exercise control over the bank accounts, accounts receivable and
inventory of AVP. The receiver liquidated all of AVP's assets and used the
proceeds therefrom for disposal of hazardous and other wastes at AVP's property
and for continued care of AVP's inventory and other payroll and non-payroll
related expenses. Upon court order dated September 22, 1998, disbursing to
various third parties the final amounts from the court supervised account and
closing such account, all remaining cash in the account, amounting to
approximately $40,000, was paid to Apotex.
On January 13, 1997, the Ft. Collins plant was conveyed to Apotex by deed
in lieu of foreclosure proceedings. In May 1997, Apotex sold the property to an
unrelated third party for $475,000, consisting of $365,000 in cash and a
one-year, interest-bearing note in the principal amount of $100,000. Even after
Apotex's receipt of proceeds from the receivership's liquidation of the assets
and Apotex's sale of the real property, the Company remained indebted to Apotex
in the amount of approximately $4,401,659 at June 30, 1997.
In addition, in 1996, the receiver caused AVP to commence an action
against John DeTemple, president and director of the Company and AVP, in the
U.S. District Court for the Eastern District of New York. The suit sought
payment of invoices in the aggregate amount of approximately $105,000 for orders
placed with AVP by J.D.T., Inc. d/b/ in American Veterinary Pharmaceuticals, an
entity which management believes to be owned by Mr. DeTemple. The
5
Company has included $25,000 in its accounts receivable in connection with this
action, which was settled in 2000 for such amount.
As a result of the failure to timely file reports under the Exchange Act
relating to the Company, the Securities and Exchange Commission may, in its
discretion, institute one or more actions against the Company and/or its
officers and directors (and former officers and directors) seeking monetary or
other penalties that may be imposed under the Exchange Act. Any such penalties
could materially adversely affect the Company.
The Company has not filed all required tax returns or paid all taxes due
since 1995. As a result of its failure to file franchise tax reports and pay
franchise taxes in New York for 1995 and 1997 through 2001, the Company was
dissolved by proclamation of the secretary of state of the state of New York on
June 27, 2002. Under New York's Tax Law, a company dissolved by proclamation may
file in the department of state a certificate of consent of the commissioner of
taxation and finance and, if the commissioner finds that all fees, taxes,
penalties and interest charges have been paid, the commissioner may grant such
consent and the dissolution is thereby effectively annulled. The Company is in
the process of making all required filings and paying all fees, taxes, penalties
and interest charges due to the state of New York in order to reinstate the
Company. Until such reinstatement, the Company is prohibited from conducting any
business. In addition, while the Company does not believe that any federal
income taxes were due for the years 1996 to 2001, the Company intends to file
the required federal income tax returns for such years and pay any amounts that
may be found to be owing for such periods.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted during the year to a vote of the security
holders of the Company through the solicitation of proxies or otherwise.
6
PART II
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
(a) Market Information: The Company's Common Stock is traded in the
over-the-counter market and is quoted on the "Pink Sheets" under the ticker
symbol "GNRX." The following table sets forth the range for high and low closing
bid quotations for the Company's Common Stock as reported by the National
Association of Securities Dealers or other qualified interdealer quotation
system. for 1996 and 1995, the years for which financial information is provided
in this Annual Report. These prices are believed to be representative
inter-dealer quotations, without, retail markup, markdown or commissions and may
not represent prices at which actual transactions occurred.
There is no established public trading market for the Common Stock. As of
the date of this report, the most recent trade date for the Common Stock was
November 15, 2001, on which date 1,100 shares were sold for $0.001 per share. In
2001, an aggregate of 408,100 shares traded on an aggregate of three trading
days at a sale price of $0.001. In 2000, an aggregate of 84,700 shares traded on
an aggregate of 10 trading days at sale prices ranging from $0.001 to $0.050. In
1999, an aggregate of 383,200 shares traded on an aggregate of 11 trading days
at sale prices ranging from $0.002 to $0.050. In 1998, an aggregate of 433,400
shares traded on an aggregate of five trading days at sale prices ranging from
$0.002 to $0.010. In 1997, an aggregate of 480,900 shares traded on an aggregate
of 12 trading days at sale prices ranging from $0.001 to $0.020.
Bid
Quarter Ended High Low
December 31, 1996 $.125 $.002
September 30, 1996 $ .25 $.125
June 30, 1996* $ .25 $ .25
March 31, 1996 $ .59 $ .25
December 31, 1995 $1.25 $ .25
September 30, 1995 $1.25 $ .25
June 30, 1995 $2.25 $ .75
March 31, 1995 $2.50 $ .50
- ----------
* Cessation of Company operations.
(b) Holders: As of December 31, 1996, there were approximately 228 holders of
record of the Company's Common Stock. As of the date of this report, there were
approximately 224 holders
7
of record of the Company's Common Stock The Company believes that, in addition,
there may be a number of beneficial owners of its stock whose shares are held in
"street name."
(c) Dividends: The Company has not paid cash dividends on its Common Stock since
inception. The payment of future dividends on its Common Stock is subject to the
discretion of the Board of Directors and is dependent on many factors, including
whether the Company establishes operations.
ITEM 6. SELECTED FINANCIAL DATA (in thousands, except per share amounts):
The Selected Financial Data presented below is for the periods from
inception of the Company through June 30, 1996, after which the then remaining
assets of the Company were sold and the Company adopted the liquidation basis of
accounting. The selected financial data set forth below should be read in
conjunction with, and are qualified by reference to, the consolidated financial
statements of the Company, and notes thereto, and Management's Discussion and
Analysis of Financial Condition and Results of Operations included elsewhere in
this Annual Report and in the Company's Annual Report on Form 10-K, as amended,
for the fiscal year ended December 31, 1995. The selected financial data as at
and for the periods ended December 31, 1995, June 30, 1996 and December 31, 1996
are derived from the consolidated audited financial statements of the Company,
including the notes thereto, included elsewhere in this Annual Report. The
selected financial data as at and for the period ended December 31, 1994 are
derived from the consolidated audited financial statements of the Company,
including the notes thereto, included and in the Company's Annual Report on Form
10-K, as amended, for the fiscal year ended December 31, 1995.
Period From July 1, 1994
January 1, 1996 (Date of Inception)
Through Year Ended to
June 30, 1996 December 31, 1995 December 31, 1994
------------- ----------------- -----------------
Net Sales $4,976
Cost of Sales 3,274
------
Gross Profit 1,702
Operating expenses:
Product development 1,093
Selling and distribution 2,149 $ 347
General and administrative 843 116
------
4,085 463
Operating loss from continuing
operations (2,383) (463)
Interest expense -- 1,069 -----
------
Loss from continuing operations -- (3,452) (463)
8
Period From July 1, 1994
January 1, 1996 (Date of Inception)
Through Year Ended to
June 30, 1996 December 31, 1995 December 31, 1994
------------- ----------------- -----------------
Discontinued Operations:
Loss from discontinued
operations until suspension of
operating activities (976) (4,461) (463)
Loss from discontinued
operations after suspension of
operating activities (1,897)
Estimated loss on disposition (150) (5,646)
--------
Loss from discontinued operations (8,552)
-------- -------- ------
Net Loss $ (1,126) $(12,004) $ (463)
======== ======== ======
Basic and Diluted (Loss) per share of
Common Stock:
Discontinued operations $ (.05) (.62)
-------- --------
Net Loss $ (.05) (.62)
Weighted average number of common
shares outstanding 20,879 19,313
======== ========
BALANCE SHEET DATA
June 30, 1996 December 31, 1995 December 31, 1994
------------- ----------------- -----------------
Working capital (deficit) (4,834) $(6,362) $ (487)
Property and equipment, net -- 352 23
Total assets 201 2,056 812
Capital deficit (4,834) (4,321)
Divisional deficit (463)
December 31, 1996
-----------------
Net Assets (liquidation basis)
Total assets $128
Net assets in liquidation 0
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
With respect to the Company's financial information set forth in this
Annual Report relating to December 31, 1996, the financial statements are
presented on a going concern basis for all periods through June 30, 1996, and on
a liquidation basis subsequent to June 30, 1996. The Company has not conducted
any business operations since the sale of AUSA on June 30,
9
1996. All activities of the Company after such date related principally to the
liquidation of the AVP assets by the receiver and the sale of the Ft. Collins
plant. All of the operations of AVP and AUSA are treated as discontinued
operations.
In connection with an inspection of its manufacturing facility from
October 1994 through May 1995 by the FDA, AVP received a "warning letter" from
the Denver District Office of the FDA setting forth certain deviations from
current good manufacturing practice regulations and alleged violations of
related provisions of the Federal Food, Drug and Cosmetic Act.
In June 1995, following new management's investigation of the matters set
forth in the warning letter, management suspended the manufacture of products
indefinitely. As a consequence of management's subsequent determination that the
time and financial commitment required to rehabilitate AVP's operations would be
too great for it to pursue, management decided to discontinue the operations of
AVP. In connection with management's decision to discontinue the operations of
AVP, the Company laid-off substantially all of its personnel at this facility
and recorded a provision of $848,000 in its 1995 financial statements. See
"Notes to Financial Statements - Note B. Discontinued Operations."
In addition, management assessed the value of goodwill acquired in
connection with the business combination compared to its carrying value. As a
result of management's determination that a significant and permanent impairment
of the goodwill associated with AVP's veterinary business occurred, the company
took a charge of $4,799,000 for the write-down of goodwill that arose in
connection with the Merger. See "Notes to Financial Statements - Note B.
Discontinued Operations."
In January 1996, the Larimer County (Colorado) District Court appointed a
receiver for AVP, including the Ft. Collins plant. The receiver liquidated
approximately all of AVP's assets at its three locations in or near Ft. Collins,
Colorado, for proceeds of approximately $670,000. The receiver used the proceeds
for disposal of hazardous and other wastes at the Ft. Collins plant and for
continued care of AVP's inventory and other payroll and non-payroll related
expenses. Upon final court order dated September 22, 1998, disbursing the final
amounts from (and then closing) the court-supervised account, all remaining
cash, amounting to approximately $40,000, was paid to Apotex. In addition,
Apotex received $475,000 from the sale of the Ft. Collins plant to an unrelated
third party in May 1997.
The Company held an auction on June 28, 1996 to sell the 100 shares of
AUSA common stock outstanding. All of such shares were subject to a perfected
security interest in favor of Apotex. The auction was held at Hill Thompson's
office at 437 Madison Avenue in New York City and the minimum price for the AUSA
shares was $1,000,000. At the auction, Apotex bid $1,000,000 for the shares of
AUSA. Apotex was the only bidder at the auction. The Company and Apotex
consummated the purchase with an effective date of July 1, 1996, promptly after
the auction.
Results of operations of AVP and AUSA are shown as "discontinued
operations" on the consolidated statement of operations. The results of
operations discussed below are those of AUSA, a former subsidiary engaged in the
distribution of injectable generic drugs primarily to hospitals, prior to June
30, 1996. Results of operations of AUSA prior to January 1, 1995 were
10
insignificant and, accordingly, no comparison between the fiscal years ended
December 31, 1995 and December 31, 1994 has been made. The Company sold AUSA to
Apotex on June 30, 1996 and therefore comparison between 1995 and 1996 relate to
the fiscal years ended December 31, 1995 and June 30, 1996, respectively.
The following should be read in conjunction with the Company's financial
statements and the related notes thereto included elsewhere herein.
RESULTS OF OPERATIONS:
Fiscal Year Ended June 30, 1996 Compared to Fiscal Year Ended December 31, 1995.
Net Sales:
Net sales for the year ended June 30, 1996, were $556,000, compared to
$4,976,000 for the year ended December 31, 1995. Prior to the sale of AUSA to
Apotex on July 1, 1996, the activities relating to AUSA during the first six
months of 1996 consisted primarily of retaining the financial services of Hill
Thompson and seeking to sell AUSA.
Operating Expenses:
Selling and Distribution:
As a result of the Company's financial difficulties, in January 1996, the
Company laid-off a substantial number of its employees in the sales department.
As a result, selling and distribution costs decreased from prior historic
levels.
General and Administrative:
General and Administrative costs decreased from prior historic levels as a
result of decreases in personnel costs.
LIQUIDITY AND CAPITAL RESOURCES
At December 31, 1995, the Company had cash and a capital deficiency of
$15,000 and $4,321,000, respectively. At June 30, 1996, the Company had cash and
a capital deficiency of $0 and $4,834,000, respectively.
At December 31, 1996 and at present, the Company lacks the liquidity to
carry on any business activities. The Company has virtually no assets and no
capital resources. Effective June 30, 1996, the Company ceased all business
operations with the sale of AUSA to Apotex. All activities of the Company after
such date related principally to the liquidation by the receiver of the AVP
assets and the sale of the Ft. Collins plant. Apotex, the Company's principal
stockholder, is currently considering various business alternatives relating to
the Company, including, but not limited to, commencing new business operations,
dissolving the Company or seeking an interested investor for a sale of its stock
holdings in the Company. There can be no assurance that Apotex will pursue any
of these or other alternatives relating to the Company or, even if it does, that
such efforts will be successful.
11
Historically, while the Company was engaged in operations, it was
dependent on Apotex for financing. At September 1996, after the sale of AUSA to
Apotex, the Company was indebted to Apotex in the amount of approximately
$4,400,000. Since 1996, the Company has not made any payments to Apotex on this
debt. Apotex has not charged interest on the indebtedness and has not instituted
any legal proceedings for collection. It is not expected that Apotex will
advance any additional funds to the Company and the Company presently has no
available financing alternatives. Notwithstanding the previous sentence, the
costs and expenses related to the preparation and filing of this Annual Report
(including, but not limited to, legal and accounting fees) and the other
Exchange Act reports being filed by the Company in an effort to comply with the
Exchange Act, will be paid by Apotex. It is not expected that Apotex will charge
the Company for such expenses.
In connection with the Merger in 1995, the Company and Apotex had entered
into lending arrangements under the Loan Agreement dated April 13, 1995. Apotex
lent the Company $500,000 in the form of a term loan and $2,000,000 in the form
of a revolving loan. Both loans were evidenced by promissory notes and would
have matured April 13, 1998. The Company borrowed the entire $2,500,000. These
loans bore interest at the rate of 1% over prime. Interest was payable on the
first business day of each March, June, September and December, and the Company
failed to pay certain accrued and unpaid interest when due. The Company secured
repayment of these amounts by all of the assets of the Company and its
subsidiaries, including AVP's plant in Fort Collins, Colorado. As additional
consideration for the loans, the Company had issued in favor of Apotex, warrants
to purchase the Company's common stock at a purchase price of $1 per share at
the rate of one share for each dollar of loan advanced. The warrants had a term
of three years.
On November 29, 1995, the Company entered into an agreement with Apotex to
amend the Loan Agreement. As amended, the Loan Agreement permitted Apotex, in
its discretion, to advance sums in excess of the $2,500,000 original loan amount
that were due December 22, 1995, but otherwise were treated as if they had been
advanced pursuant to the Loan Agreement. The Company requested additional
advances and Apotex advanced the Company approximately $325,000 through December
31, 1995. The Company agreed that failure to repay the amounts when due would
constitute a default under the Loan Agreement. The Company also issued to Apotex
a warrant to purchase an additional 813,783 shares of the Company's common stock
at an exercise price of $.75 per share in connection with the amendment. The
warrants had a term of three years.
At December 31, 1995, the Company was indebted to Apotex for an aggregate
of $3,563,000, including $447,000 of accounts payable converted to notes
pursuant to the amendment to the Loan Agreement. The Company's failure to pay
the amounts due December 22, 1995 constituted an Event of Default under the Loan
Agreement and Apotex, by a letter dated January 2, 1996, accelerated the entire
amount of indebtedness of the Company and its subsidiaries, which were jointly
and severally liable for the debt. As a result of the acceleration, on January
5, 1996, the Company turned over to Apotex all of the collateral securing the
loans under the Loan Agreement, as amended. The Company continued to receive
additional advances from Apotex in 1996 in the aggregate amount of $862,000. At
June 30, 1996, the Company was indebted to Apotex for an aggregate of $5,296,659
(before the sale of AUSA) including
12
$747,423 of accounts payable converted to notes pursuant to the Loan Agreement,
as amended. The sale of AUSA reduced the Company's indebtedness to Apotex by
$1,000,000.
On January 4, 1996, Apotex sought and received the appointment of a
receiver for AVP's Ft. Collins plant in a proceeding in Larimer County,
Colorado. The order permitted the receiver to exercise control over AVP's bank
accounts, accounts receivable and inventory. As a result of the November 29,
1995 amendment to the Loan Agreement and the appointment of a receiver, AVP
stopped receiving any cash proceeds from the Apotex loans. AVP subsequently
discontinued operations. See "Business - Discontinued Operations of AVP" above.
In addition, pursuant to the Loan Agreement, as amended, accounts receivable of
AUSA were assigned to Apotex and collections thereof were deposited into the
bank accounts of Apotex. Apotex subsequently purchased all of the outstanding
capital stock of AUSA on July 1, 1996. See "Business - Sale of AUSA" above.
Although Apotex's acquisition of AUSA from the Company resulted in a reduction
of the Company's indebtedness in favor of Apotex, approximately $4,400,000 of
indebtedness remained outstanding after the sale of AUSA to Apotex.
The receiver liquidated all of AVP's assets and used the proceeds
therefrom for disposal of hazardous and other wastes at AVP's property and for
continued care of AVP's inventory and other payroll and non-payroll related
expenses. Upon final court order in September 1998, all cash remaining in the
court supervised account from the liquidation of the assets and other property
and/or settlement of liabilities, amounting to approximately $40,000, was paid
to Apotex. In addition, Apotex received $475,000 as a result of the sale of the
Ft. Collins plant to a third party in May 1997.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
See Index to Financial Statements after signature page.
ITEM 9. CHANGES IN AND DISAGREEMENT WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
None.
PART III.
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
Prior to May 1997, Jack H. Schramm, then 48, was sole Director of the
Company and Acting President and Chief Executive Officer of the Company. Mr.
Schramm had served as a Director of the Company since April 13, 1995 and as
Acting President and Chief Executive Officer of the Company since January 1996.
Mr. Schramm was a Director of Apotex, the Company's majority shareholder and
primary creditor, from 1993 to May 1997. From 1993 through January 1996, Mr.
Schramm was Executive Vice President of Apotex and from January 1996 to May
1997, President of Apotex. From 1991 to 1993, Mr. Schramm was a financial and
international marketing consultant to Genpharm, a Canadian pharmaceutical
company. From
13
1982 to 1990, Mr. Schramm was Senior Vice President of Joffee Lasalle Company, a
Manhattan commercial real estate firm.
On May 1, 1997, Jack Margareten, then Chief Financial Officer of the
Company and Apotex, replaced Mr. Schramm as sole Director and Acting President
of the Company and Apotex. Mr. Margareten has been Chief Financial Officer of
the Company and Apotex since April 1996. Mr. Margareten's services for the
Company have been performed on a part-time, as needed basis since the Company's
cessation of operations in June 1996. Since December 26, 1999, Mr. Margareten
has served in a full-time capacity as Chief Operating Officer of Fashion
Accessory Bazaar, LLC, a privately held company. Prior to such date, Mr.
Margareten was self-employed in personal investments.
ITEM 11. EXECUTIVE COMPENSATION
In December 1995, the Company discontinued the operations of AVP and laid
off its AVP employees. In June 1996, the Company sold AUSA to Apotex. As a
result, the Company has no business operations and does not employ any employees
or executive officers for compensation. Jack Margareten is Chief Financial
Officer and Acting President of the Company and, since the Company's cessation
of operations, has been compensated by Apotex for any services rendered on
behalf of or for the Company. Such services and related compensation have been
minimal.
The following table sets forth a summary for the years ended June 30, 1996
and December 31, 1995 and 1994, of the cash compensation paid by the Company, as
well as certain other compensation paid or accrued during such years, to the
Company's executive officers.
Long Term
Annual Compensation Compensation
------------------------------------------------ ------------
Name and Other Options
Principal Annual (# of
Position Year Salary Bonus Compensation Shares)
- -------- ---- ------ ----- ------------ -------
Jack H. Schramm 1996 50,000 None None None
Acting President(1) 1995 None None None None
1994 None None None None
Richard J. Strobel 1996 None None None None
Vice President 1995 $68,855 None None 30,000
Finance & Admin. and 1994 None None None None
Assistant Secretary(2)
John R. Toedtman 1996 None None None None
Chief Executive 1995 $119,000 None None None
Officer(3) 1994 $88,000 None None None
John J. DeTemple 1996 None None None None
President(4) 1995 $28,000 None None None
14
Long Term
Annual Compensation Compensation
------------------------------------------------ ------------
Name and Other Options
Principal Annual (# of
Position Year Salary Bonus Compensation Shares)
- -------- ---- ------ ----- ------------ -------
1994 $125,000 None None None
1993 $ 90,000 None None $150,000
Jack Margareten
Chief Financial
Officer(5) 1996 $ 80,000(5) None None None
(1) Jack H. Schramm served as Acting President and Chief Executive Officer
from January 1996 to May 1997. Mr. Schramm's salary, as well as any
business expenses incurred by Mr. Schramm, were considered expenses of
Apotex. Does not include warrants to purchase 50,000 shares of common
stock of the Company at $1.50 per share that Mr. Schramm received in
connection with the Merger. These warrants have expired.
(2) Richard J. Strobel served as Vice President, Finance and Administration
from April 13, 1995 until 1996. For his service in this capacity, Mr.
Strobel received an annual salary of $100,000.
(3) John Toedtman served as President of the Company and each of its
subsidiaries from April 13, 1995 through January 8, 1996, at an annual
salary of $150,000 and as director of GEN/Rx, AVP and Collins for each of
1996, 1995 and 1994. Effective January 8, 1996, Mr. Toedtman resigned from
all of his capacities served with the Company. Prior to April 13, 1995,
Mr. Toedtman served as Chief Executive Officer.
(4) John DeTemple served as President of the Company and each of its
subsidiaries until April 12, 1995 and as director of GEN/Rx, AVP and
Collins until December 31, 1995. Effective December 31, 1995, Mr. DeTemple
resigned as director of the Company.
(5) In April 1996, Jack Margareten replaced Richard J. Strobel as Chief
Financial Officer. Mr. Margareten's salary, as well as any business
expenses incurred by Mr. Margareten, were considered expenses of Apotex.
Steven E. Novick served as Director of the Company and each of its
subsidiaries from April 13, 1995 through January 10, 1996. Since 1993, Mr.
Novick was President and Chief Executive Officer of Apotex. On January 10, 1996,
Mr. Novick resigned from all capacities served with the Company and Apotex. Mr.
Novick received no remuneration for his capacities served with the Company.
Employment Agreements:
The Company does not have any employment agreements.
Stock Option Grants in 1996:
None
Directors Compensation
15
Directors who are officers or employees of the Company are not compensated
and do not receive expense reimbursement for their service as a director. John
DeTemple received an aggregate of $45,000 for services as a director for the
year ended December 31, 1995.
Compensation Committee Interlocks and Insiders Participation
None of the Company's executive officers has served on the Board of
Directors or on the Compensation Committee of any other entity, any of whose
officers served on the Board of Directors of the Company.
From April 13, 1995 to May 1997, Mr. Schramm was a director of the Company
and Apotex. Mr. Novick was a director of the Company and Apotex from April 13,
1995 until his resignation on January 10, 1996.
Compliance with Section 16(a) of the Securities Exchange Act of 1934
Section 16(a) of the Securities Exchange Act of 1934, as amended, requires
the Company's officers and directors, and persons who own more than 10% of a
registered class of the Company's equity securities, to file reports of
ownership and changes in ownership with the Securities and Exchange Commission,
copies of which are required by regulation to be furnished to the Company.
Based solely on review of the copies of such forms furnished to the
Company, the Company believes that during fiscal 1996 its officers, directors
and ten percent (10%) beneficial owners complied with all Section 16(a) filing
requirements.
PERFORMANCE GRAPH
The following graph provides a comparison on a cumulative basis of the
yearly percentage change over the five fiscal years ending with the fiscal year
ended December 31, 1996 in (a) the total Stockholder return on the Company's
Common Stock with (b) the total return on the Dow Jones Equity Market Index and
(c) the total return of the Dow Jones Pharmaceutical Index. Such yearly
percentage change has been measured by dividing (1) the sum of (A) the amount of
dividends for the measurement period, assuming dividend reinvestment, and (B)
the difference between the price per share at the end and at the beginning of
the measurement period, by (ii) the price per share at the beginning of the
measurement period. The comparisons are based on historical data and are not
intended to forecast the future performance of the Company's Common Stock.
ASSUMES $100 INVESTED ON JANUARY 1, 1991
ASSUMES DIVIDEND REINVESTED
FISCAL YEAR ENDING December 31, 1996
Index Description 1991 1992 1993 1994 1995 1996
- ----------------- ---- ---- ---- ---- ---- ----
GEN/Rx, Inc. 100 78.34 100.48 76.64 17.11 0.14
16
Dow Jones Equity
Market Index 100 109 119 120 166 206
Dow Jones
Pharmaceutical Index 100 82 76 87 143 179
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table provides information regarding beneficial ownership of the
Company's Common Stock as of May 22, 2003: (i) by each person who owns or is
known by the Company to own beneficially five (5%) percent or more of the
Company's outstanding Common Stock; (ii) by all directors; and (iii) by all
directors and executive officers of the Company as a group.
Shares Owned Percentage of
Name and Address of Beneficially and Outstanding Shares
Beneficial Owner Of Record(1) Of Common Stock
---------------- --------- ---------------
Apotex USA, Inc. 15,353,840(2) 73.5%
1776 Broadway, Suite 1900
New York, NY 10019
John R. Toedtman(3) 1,073,003 5.7%
11 Birch Drive
Basking Ridge, NJ 07920
Jack Margareten
600 Woodmere Boulevard
Woodmere, NY 11598 0 *
All Executive Officers
and Directors (1 person) 0 *
- ------------------
* Less than 1%
(1) Pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as
amended, beneficial ownership of a security consists of sole or shared
voting power (including the power to vote or direct the voting) and/or
sole or shared investment power (including the power to dispose or direct
the disposition) with respect to a security whether through a contract,
arrangement, understanding, relationship or otherwise. Unless otherwise
indicated, herein, each person has sole power to vote or dispose or direct
the disposition of the shares owned beneficially.
17
(2) Excludes: (i) 3,313,783 shares issuable upon exercise of warrants to
acquire 2,500,000 shares at an exercise price of $1.00 per share and
813,783 shares at an exercise price of $.75 per share; and (ii) an
aggregate of 270,000 shares subject to warrants (exercisable at $1.50 per
share) granted to 12 persons who were employees of or consultants to
Apotex at April 12, 1995, the date of the Merge. None of these warrants
were exercised and all of these warrants were either cancelled or have
expired by their terms.
(3) John Toedtman served as President of the Company and each of its
subsidiaries from April 13, 1995 through January 8, 1996, and as a
director of the Company, AVP and Collins for each of 1995 and 1994.
Effective January 8, 1996, Mr. Toedtman resigned from all capacities
served with the Company.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
On April 13, 1995, the Merger of GEN/Rx, Inc.'s newly formed wholly-owned
subsidiary, GEN/Rx Acquisition Subsidiary, Inc., with and into AUSA was
consummated. Pursuant to the Merger, the Company acquired all the assets of
AUSA, a company engaged in the distribution of injectable drugs to the hospital
market. AUSA was a subsidiary of Apotex. As part of the Merger transaction, the
Company issued to Apotex 15,353,840 shares of its Common Stock. As a result,
Apotex became the owner of approximately seventy four (74%) percent of the
outstanding Common Stock of the Company. In addition, warrants to purchase
270,000 shares of common stock of GEN/Rx for $1.50 per share were issued to
various individuals in connection with the Merger.
Since the former shareholders of AUSA own 74% of GEN/Rx, Inc., the
transaction was accounted for as if AUSA acquired the net assets of GEN/Rx for
the previously issued and outstanding shares of GEN/Rx.
In connection with the Merger, pursuant to the Loan Agreement dated April
13, 1995 between the Company and Apotex, Apotex lent the Company $500,000
represented by a Term Note dated April 13, 1995 and $2,000,000 represented by a
revolving line of credit note dated April 13, 1995. The notes bore interest at
1% over prime and would have matured on April 13, 1998. These notes were secured
by all of the assets of the Company and its subsidiaries, including AVP's Ft.
Collins plant. As additional consideration for the loans, Apotex received
warrants exercisable at $1.00 per share to purchase shares of the Company's
common stock in an amount equal to one share for each dollar advanced pursuant
to the Loan Agreement. The warrants had a term of three years. The Company
borrowed the entire $2,500,000 pursuant to the Loan Agreement.
On November 29, 1995, the Company entered into an agreement with Apotex to
amend the Loan Agreement. As amended, the Loan Agreement permitted Apotex, in
its discretion, to advance sums in excess of the $2,500,000 original loan
amount, that were due December 22, 1995, but otherwise were treated as if they
had been advanced pursuant to the Loan Agreement. The Company requested
additional advances and Apotex advanced the Company approximately $325,000
through December 31, 1995. The Company agreed that failure to repay the amounts
when due would constitute a default under the Loan Agreement. The Company also
issued to Apotex a warrant to purchase an additional 813,783 shares of the
Company's common stock at
18
an exercise price of $.75 per share in connection with the amendment. The
warrants had a term of three years.
The Company's failure to pay the amounts due December 22, 1995 constituted
an Event of Default under the Loan Agreement and by letter dated January 2,
1996, Apotex accelerated the entire amount of indebtedness of the Company and
its subsidiaries, which were jointly and severally liable for the debt. As a
result of the acceleration, on January 5, 1996, the Company turned over to
Apotex all of the collateral securing the loans under the Loan Agreement. The
Company continued to receive additional advances from Apotex in 1996 in the
aggregate amount of $862,000.
On January 4, 1996, Apotex sought and received the appointment of a
receiver for the Ft. Collins plant in a proceeding in Larimer County, Colorado.
The order permitted the receiver to exercise control over AVP's bank accounts,
accounts receivable and inventory. As a result of the November 29, 1995
amendment to the Loan Agreement and the appointment of a receiver, AVP stopped
receiving any cash proceeds from the Apotex loans. AVP subsequently discontinued
operations. In addition, pursuant to the Loan Agreement, as amended, accounts
receivable of AUSA were assigned to Apotex and collections thereof were
deposited into the bank accounts of Apotex. On June 30, 1996, Apotex purchased
from the Company at an auction all of the outstanding shares of AUSA for $1
million. On January 13, 1997, AVP conveyed the Ft. Collins plant to Apotex in
lieu of foreclosure proceedings.
Interest expense incurred on the Apotex loans for the year ended December
31, 1995 approximated $1,067,000, including imputed interest assigned to the
value of the warrants issued to Apotex of $915,000. During 1996 and thereafter,
Apotex ceased charging interest on any indebtedness of the Company in favor of
Apotex.
Prior to June 30, 1996, the Company utilized the service of certain
employees of Apotex in the areas of product development, quality assurance,
regulatory affairs, management information systems, purchasing and other
clerical work. As compensation for these services, AUSA paid to Apotex its
pro-rata portion of the salary and related benefits of these individuals. The
cost incurred for these services for the year ended December 31, 1995 was
$352,000. In addition, AUSA reimbursed Apotex for a portion of the occupancy
costs incurred in connection with the building occupied by Apotex regulatory
affairs, and personnel. The costs incurred for these services for the year ended
December 31, 1995 was $65,265. During 1996 and thereafter, Apotex did not charge
the Company for any of such services.
In addition, the Company occupied office space as a subtenant of Apotex,
although no formal agreement existed. The Company's monthly rent (paid directly
to the landlord) was equivalent to the rent provided in the lease agreement
between Apotex and the landlord.
The Company entered into a Separation and Release Agreement dated as of
November 6, 1996, by and among Jack Schramm, former President and Chief
Executive Officer of the Company, Apotex., the Company and Apotex USA
Injectables, Inc. (f/k/a AUSA, Inc.), as amended by Addendum No.1 thereto dated
as of April 21, 1997 (collectively, the "Separation Agreement"). Under the
Separation Agreement, as partial consideration for Jack Schramm's release of
claims against the Company and its affiliates, Apotex agreed to pay Mr. Schramm
19
salary and benefits, at the rate in effect on October 1, 1996, from the date of
the Separation Agreement through December 31, 1997. The Separation Agreement
also called for Apotex to pay Mr. Schramm $750 per day for any consulting
services provided by Mr. Schramm to Apotex or Apotex USA Injectables and for Mr.
Schramm to receive a certain percentage of profits generated in connection with
a certain project. Under Addendum No. 1 to the Separation Agreement, the parties
agreed that Mr. Schramm would be entitled to receive $13,809.50 in full
satisfaction of the payment obligations relating to such certain project. In
addition, under the Separation Agreement, Mr. Schramm waived any rights to
purchase shares of common stock of the Company under any warrants of the Company
and the Company agreed to pay Mr. Schramm, on a one-time basis, 10% of the net
proceeds received from any business combination or capital transaction involving
the Company effected by either Mr. Schramm or Hill Thompson Capital Markets.
Since the Company's cessation of operations in June 1996, Jack Margareten,
the Company's Chief Financial Officer and Acting President, has been compensated
by Apotex for any services rendered or out of pocket expenses incurred on behalf
of or for the Company. Such services and related compensation have been minimal.
It is not expected that Apotex will charge the Company for such expenses.
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a)(1)&(2) Financial Statements.
See Index to Financial Statements after Signature Page.
(a)(3) Exhibits.
2.5 Amended and Restated Master Agreement dated April 13, 1995. (Filed as
Exhibit 2.5 to the Company's Annual Report on Form 10-K, as amended, for
the fiscal year ended December 31, 1995.)
2.7 Plan and Agreement of Merger dated April 13, 1995. (Filed as Exhibit 2.7
to the Company's Annual Report on Form 10-K, as amended, for the fiscal
year ended December 31, 1995.)
2.25 Verified Complaint for Appointment of Receiver in Case No. 96CV3 Apotex
USA Inc. v. American Veterinary Products Inc. (Filed as Exhibit 2.25 to
the Company's Annual Report on Form 10-K, as amended, for the fiscal year
ended December 31, 1995.)
2.27 Order Appointing Receiver in Case No. 96CV3 Apotex USA Inc. v. American
Veterinary Products Inc. (Filed as Exhibit 2.27 to the Company's Annual
Report on Form 10-K, as amended, for the fiscal year ended December 31,
1995.)
2.28 First Amended Complaint in Case No. 96CV3 Apotex USA Inc. v. American
Veterinary Products Inc. and 1st Choice Bank.
20
2.29 1st Choice Bank's Answer, Counterclaim and Amended Cross Claim in Response
to First Amended Complaint in Case No. 96CV3 Apotex USA Inc. v. American
Veterinary Products Inc. and 1st Choice Bank.
2.30 Stipulation Authorizing Sales of Assets dated June 7, 1996 by Receiver,
Apotex USA, Inc. and 1st Choice Bank and Order approving Stipulation dated
June 7, 1996 in Case No. 96CV3 Apotex USA Inc. v. American Veterinary
Products Inc. and 1st Choice Bank.
2.31 Order Regarding Payment of Certain Expenses in Case No. 96CV3 Apotex USA
Inc. v. American Veterinary Products Inc. and 1st Choice Bank.
2.32 Final Report of Receiver in Case No. 96CV3 Apotex USA Inc. v. American
Veterinary Products Inc. and 1st Choice Bank.
2.33 Order dispersing funds and dismissing all claims between Apotex and First
Choice in Case No. 96CV3 Apotex USA Inc. v. American Veterinary Products
Inc. and 1st Choice Bank and attaching Settlement Agreement.
10.2 Separation and Release Agreement dated as of November 6, 1996 among Jack
Schramm and Apotex USA Inc., Gen/Rx, Inc. and Apotex USA Injectables, Inc.
(f/k/a AUSA, Inc.).
10.3 Addendum No. 1 dated as of April 21, 1997 to Separation and Release
Agreement dated as of November 6, 1996 among Jack Schramm and Apotex USA
Inc., Gen/Rx, Inc. and Apotex USA Injectables, Inc. (f/k/a AUSA, Inc.).
16 Letter regarding change in accountants. (Filed as an exhibit to the
Company's Current Report on Form 8-K dated July 10, 1995.)
99.1 Certification
21
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
Dated: May 22, 2003 GEN/RX, Inc.
By: /s/ Jack Margareten
-----------------------------
Jack Margareten
Acting President
Pursuant to the requirements of the Securities Exchange Act of 1934, this report
has been signed by the following persons on behalf of the Registrant in the
capacities and on the dates indicated.
Signature Title Date
--------- ----- ----
/s/ Jack Margareten Acting President and Chief Executive May 22, 2003
- ------------------------ Officer, Chief Financial Officer and
Jack Margareten Sole Director
CERTIFICATIONS
I, Jack Margareten, certify that:
1. I have reviewed this annual report on Form 10-K of GEN/Rx, Inc.;
2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report; and
3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report.
Dated: May 22, 2003 /s/ Jack Margareten
-----------------------------------
Jack Margareten
Acting President and Chief
Executive Officer and Chief
Financial Officer
22
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND SCHEDULE
FILED WITH THE ANNUAL REPORT OF THE COMPANY ON FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 1996
INCLUDED IN PART II:
Page
----
Report of Independent Public Accountants F-2
Consolidated Statement of Net Assets (liquidation basis) as of F-3
December 31, 1996
Consolidated Statement of Changes in Net Assets (liquidation basis) F-4
for the period July 1, 1996 through December 31, 1996
Consolidated Balance Sheets at June 30, 1996 and December 31, 1995 F-5
Consolidated Statements of Operations for the period January 1, 1996 F-6
through June 30, 1996, the year ended December 31, 1995 and for the
period July 1, 1994 (inception) through December 31, 1994
Consolidated Statements of Cash Flows for the period January 1, 1996 F-7
through June 30, 1996, the year ended December 31, 1995 and for the
July 1, 1994 (inception) through December 31, 1994
Consolidated Statement of Changes in Capital Deficit for the period F-8
January 1, 1996 through June 30, 1996, the year ended December 31,
1995 and for the period July 1, 1994 (inception) through December
31, 1994
Notes to Consolidated Financial Statements F-9
through
F-15
----------
Other financial statement schedules are omitted because the conditions requiring
their filing do not exist or the information required thereby is included in the
financial statements filed, including the notes thereto
REPORT OF INDEPENDENT AUDITORS
Board of Directors and Shareholders
Gen/Rx, Inc.
New York, New York
We have audited the accompanying consolidated balance sheets of Gen/Rx, Inc. and
subsidiaries, as of June 30, 1996 and December 31, 1995, and the related
consolidated statements of operations, cash flows and changes in capital deficit
for the period from January 1, 1996 through June 30, 1996, the year ended
December 31, 1995 and the period from July 1, 1994 (date of inception) to
December 31, 1994. In addition, we have audited the accompanying statement of
net assets (liquidation basis) as of December 31, 1996 and the related statement
of changes in net assets (liquidation basis) for the period from July 1, 1996
through December 31, 1996. These financial statements are the responsibility of
the Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements enumerated above present fairly, in all
material respects, the consolidated financial position of Gen/Rx, Inc. and
subsidiaries as of June 30, 1996 and December 31, 1995, the consolidated results
of their operations and their consolidated cash flows for the period from
January 1, 1996 through June 30, 1996, the year ended December 31, 1995 and the
period from July 1, 1994 (date of inception) to December 31, 1994 and the net
assets (in liquidation) as of December 31, 1996 and changes in net assets (in
liquidation) for the period from July 1, 1996 to December 31, 1996 in conformity
with accounting principles generally accepted in the United States of America.
As described in Note A to the financial statements, the operations of one of the
Company's subsidiaries were discontinued in December 1995 and the subsidiary was
put into receivership in January 1996. In addition, the Company sold its
remaining operating subsidiary in an auction and therefore, effective July 1,
1996, the Company has changed its basis of accounting for periods subsequent to
June 30, 1996 from the going concern basis to a liquidation basis.
Richard A. Eisner & Company, LLP
New York, New York
October 24, 2002
F-2
GEN/RX, INC.
Consolidated Statement of Net Assets
(liquidation basis)
December 31, 1996
(in thousands, except shares and per shares amounts)
ASSETS
Cash $ 61
Accounts receivable 25
Fixed assets held for sale, at estimated net realizable value 42
-------
128
LIABILITIES
Accrued expenses and taxes 128
-------
Commitments and contingencies
Net assets in liquidation $ 0
=======
Net assets in liquidation per common share (based on 20,878,711
common shares outstanding) $ 0
=======
See notes to financial statements
F-3
GEN/RX, INC.
Consolidated Statement of Changes in Net Assets
(liquidation basis)
For the Period From July 1, 1996 Through December 31, 1996
(in thousands, except shares and per share amounts)
Net deficit - June 30, 1996 $(4,834)
Adjustment of liabilities for estimated amount to be paid 4,834
-------
Net assets in liquidation - December 31, 1996 $ 0
=======
See notes to financial statements
F-4
GEN/RX, INC.
Consolidated Balance Sheets
(in thousands, except shares and per share amounts)
(Notes A and B)
June 30, December 31,
1996 1995
---------- ------------
ASSETS
Current Assets:
Cash $ 15
Assets of discontinued operations (Note D) $ 201 2,041
---------- ----------
$ 201 $ 2,056
========== ==========
LIABILITIES AND CAPITAL DEFICIT
Current liabilities:
Notes payable - Apotex (Note H and K) $ 4,321 $ 3,563
Estimated liabilities of discontinued operations (Note D) 714 2,814
---------- ----------
Total current liabilities 5,035 6,377
---------- ----------
Commitment, contingencies and other matters (Note L)
Capital deficit:
Common stock, par value $.004 per share, authorized
20,000,000 shares; issued and outstanding 20,878,711 shares 84 84
Additional paid-in capital 8,502 7,889
Accumulated deficit (13,420) (12,294)
---------- ----------
Total capital deficit (4,834) (4,321)
---------- ----------
$ 201 $ 2,056
========== ==========
See notes to financial statements
F-5
GEN/RX, INC.
Consolidated Statements of Operations
(in thousands, except shares and per share amounts)
(Notes A and B)
Period from
July 1, 1994
(Date of
Period From Inception)
January 1, 1996 Year Ended To
Through December 31, December 31,
June 30, 1996 1995 1994
--------------- ------------ ---------------
Discontinued operations (Note B):
Loss from discontinued operations until suspension of
operating activities $ (976) $ (4,461) $ (463)
Loss from discontinued operations during
suspension of operating activities (1,897)
Estimated loss on disposition (150) (5,646)
---------- ----------
Loss from discontinued operations (1,126) (12,004) (463)
---------- ---------- ----------
Net loss $ (1,126) $ (12,004) $ (463)
========== ========== ==========
Basic and diluted loss per share of common stock:
Discontinued operations $ (.05) $ (.62)
---------- ----------
Net loss per share $ (.05) $ (.62)
========== ==========
Weighted average number of common shares
outstanding 20,879 19,313
========== ==========
See notes to financial statements
F-6
GEN/RX, INC.
Consolidated Statements of Cash Flows
(in thousands, except shares and per share amounts)
(Notes A and B)
Period from
July 1, 1994
(Date of
Period From Inception)
January 1, 1996 Year Ended To
Through December 31, December 31,
June 30, 1996 1995 1994
------------- ------------ -------------
Cash flows from operating activities:
Net Loss $ (1,126) $(12,004) $ (463)
Adjustments to reconcile net loss to net cash
used in discontinued operations:
Estimated loss on disposition 150 5,646
Changes in assets and estimated liabilities
of discontinued operations (1,670) 4,307 (785)
-------- -------- --------
Net cash used in discontinued operations $ (2,646) $ (2,051) $ (1,248)
-------- -------- --------
Cash flows from investing activities:
Capital expenditure in discontinued operations (379) (23)
-------- --------
Cash flows from financing activities:
Proceeds from advances - Apotex 2,631 1,275
Proceeds from notes payable - Apotex 3,033
Principal payments under notes payable - Apotex (248)
Net cash used in discontinued operations (344)
--------
Net cash provided by financing activities 2,631 2,441 1,275
-------- -------- --------
Net (decrease) increase in cash (15) 11 4
Cash at beginning of period 15 4 0
-------- -------- --------
Cash at end of period $ 0 $ 15 $ 4
======== ======== ========
See notes to financial statements
F-7
GEN/RX, INC.
Consolidated Statements of Changes in Capital Deficit
(in thousands, except shares and per share amounts)
(Notes A and B)
Common Stock
-----------------------------
Number
of Additional Accumulated Divisional
Shares Amount Capital Deficit Deficit
------------ ------------ ------------ ------------ ------------
Balance - July 1, 1994 (inception) 0 $ 0 $ 0 $ 0 $ 0
Net loss for the period July 1, 1994
(inception) through December 31, 1994 (463)
------------ ------------ ------------ ------------ ------------
Balance - December 31, 1994 0 0 0 0 (463)
Net income for period January 1, 1995
through April 3, 1995 290
Capital contribution 1,673
Shares issued April 3, 1995 upon
incorporation 1 1,673 (173) (1,500)
Shares canceled April 13, 1995 in
connection with merger (1) (1,673) 1,673
Shares issued April 13, 1995 in
connection with merger 13,289 53 4,498
Shares to be issued in connection with
merger 2,065 9
Issued and outstanding Gen/Rx shares 5,525 22 654
Issuance of warrants 947
Net income (loss) for the period from April 4,
1995 through December 31, 1995 290 (12,294)
------------ ------------ ------------ ------------ ------------
Balance - December 31, 1995 20,879 84 7,889 (12,294) 0
Net loss for the period ended June 30, 1996
Sale of AUSA to Apotex USA, Inc. 613 (1,126)
------------ ------------ ------------ ------------ ------------
Balance - June 30, 1996 20,879 $ 84 $ 8,502 $ (13,420) $ 0
============ ============ ============ ============ ============
See notes to financial statements
F-8
GEN/RX, INC.
Notes to Financial Statements
December 31, 1996 and 1995
NOTE A - THE COMPANY
Gen/Rx, Inc. ("GEN/Rx"), through its wholly-owned subsidiaries AUSA, Inc.
("AUSA") and American Veterinary Products Inc. ("AVP"), was formerly engaged in
the distribution of generic pharmaceutical products and veterinary products.
The consolidated financial statements include the accounts of AUSA, and from
April 13, 1995, its parent GEN/Rx, and AVP. References herein to the "Company"
refer to AUSA, Gen/Rx and AVP, collectively (see Note C regarding business
combination).
[1] AUSA:
On July 1, 1996, pursuant to an auction Gen/Rx sold its shares of the
capital stock of AUSA in exchange for $1 million on indebtedness owed to
Apotex USA Inc., a Delaware corporation ("Apotex USA"), the Company's
principal shareholder and principal creditor. No gain or loss was recorded
upon the sale as the transaction was with the Company's principal
shareholder. Accordingly, the difference between the indebtedness and the
carrying amount of the subsidiary was treated as a capital contribution.
Although Apotex USA's acquisition of AUSA from the Company resulted in a
reduction of the Company's indebtedness in favor of Apotex USA,
approximately $4 million of indebtedness remained outstanding after the
sale.
[2] AVP:
In connection with an inspection of its manufacturing facility from
October 1994 through May 1995 by the U.S. Food and Drug Administration
("FDA"), AVP received a "warning letter" from the Denver District Office
of the FDA setting forth certain alleged deviations from current good
manufacturing practice regulations and alleged violations of related
provisions of the Federal Food, Drug and Cosmetic Act.
In June 1995, following management's investigation of the matters set
forth in the warning letter, management suspended the manufacture of
products indefinitely. In December 1995, management decided to discontinue
the operations of AVP. In connection with the decision during the fourth
quarter of 1995 to dispose of AVP, the Company laid-off substantially all
of its personnel at AVP's facility and recorded a charge of $848,000
consisting of a provision for estimated loss on disposition of AVP's
assets of $398,000, a provision for estimated operating losses of $450,000
from AVP's business through the expected time of disposition and the
write-off of goodwill that arose in connection with the merger (Note C)
applicable to AVP's business of $4,798,000. AVP was put into receivership
in January 1996 by Apotex USA, its principal secured creditor.
The receiver liquidated all of AVP's assets. Upon final court order, after
all liabilities of the receivership including receivers fees of $10,176
were paid, all remaining cash, amounting to approximately $40,000, was
paid to Apotex USA.
[3] Basis of presentation:
For all periods through June 30, 1996, the financial statements have been
prepared on a going concern basis. Subsequent to June 30, 1996, the
Company has adopted the liquidation basis of accounting. Accordingly, the
net assets of the Company at December 31, 1996 are stated at liquidation
value, whereby assets are stated at their estimated net realizable values
and liabilities, which include estimated liquidation expenses to be
incurred through the date of final dissolution of the Company, are stated
at their anticipated settlement amounts.
F-9
GEN/RX, INC.
Notes to Financial Statements
December 31, 1996 and 1995
NOTE B - DISCONTINUED OPERATIONS
Results from discontinued operations are as follows (in thousands):
AVP
---------------
Period From
April 13, 1995 AUSA
(Date of ---------------------
Acquisition) Year Ended
Year Ended Through December 31,
December 31, December 31, ---------------------
1996 1995 1996 1995
------------ --------------- --------- --------
Net sales $ 779 $ 556 $ 4,976
Loss from discontinued operations (2,906)(a) (976) (3,452)
Gain on sale of AUSA 1,541
Provision for loss on disposition $(150) (5,646)
Total (loss) income from (150) (8,552) 565 (3,452)
discontinued operations
(a) Includes losses of $1,897 incurred from the period July 1, 1995 when
operating activities were suspended, through December 31, 1995.
The assets and estimated liabilities of the discontinued operations have been
reclassified on the balance sheet to separately identify them and consist of the
following (in thousands):
AVP AUSA
------------------------ ------------
June 30, December 31, December 31,
1996 1995 1995
--------- ------------- ------------
Cash $ 84 $ 155
Accounts receivable, net 41 243 $ 539
Inventories 158 24
Fixed assets 76 500 352
Other assets 3 67
------ ------ ------
Total assets $ 201 $1,059 $ 982
====== ====== ======
Notes payable - banks $ 121 $ 137
Accounts payable 547 587 $ 887
Accrued expenses and other liabilities 46 273 480
Estimated costs of disposal 450
------ ------ ------
Total estimated liabilities $ 714 $1,447 $1,367
====== ====== ======
As a result of management's determination that a significant and permanent
impairment of the goodwill associated with AVP's veterinary business occurred,
the Company took a charge of $4,798,000 in the fourth quarter for the write-down
of goodwill that arose in connection with the merger applicable to AVP's
business (see Note C). Such charge is included in the estimated loss of disposal
of discontinued operations on the consolidated statement of operations.
F-10
GEN/RX, INC.
Notes to Financial Statements
December 31, 1996 and 1995
NOTE C - BUSINESS COMBINATION
On April 13, 1995, a merger (the "Merger") of GEN/Rx, Inc., with an into AUSA
was consummated. Pursuant to the Merger, GEN/Rx acquired all the assets of AUSA,
which commenced operations as Yorpharm, a division of Apotex, in July 1994. In
April 1995, prior to the Merger, the net assets of Yorpharm were transferred to
the newly formed corporation, AUSA a subsidiary of Apotex. As part of the Merger
transaction, GEN/Rx issued to Apotex (the former shareholder of AUSA) 13,288,874
shares of its common stock and was obligated to issue to Apotex, an additional
2,064,966 shares as soon as practicable following an amendment to the Company's
Certificate of Incorporation increasing the number of authorized shares of
common stock. After issuance of the additional shares, Apotex owned
approximately seventy four (74%) percent of the outstanding common stock of
GEN/Rx. In addition, warrants to purchase 270,000 shares of common stock of
GEN/Rx for $1.50 per share were issued to various individuals in connection with
the Merger.
Since, after issuance of the additional 2,064,966 shares upon amendment to the
Company's Certificate of Incorporation increasing the number of authorized
shares, the former shareholders of AUSA owned 74% of GEN/Rx, the transaction was
accounted for as if AUSA acquired the net assets of GEN/Rx for the previously
issued and outstanding shares of GEN/Rx. Accordingly, the financial statements
presented herewith are those of AUSA. The Merger was accounted for as a purchase
of GEN/Rx for $5,711,000. The excess of the fair value of the previously issued
and outstanding stock of GEN/Rx, Inc. over the fair value of its assets of
$5,036,000 was recorded as goodwill (see Note H).
In addition, in connection with the Merger and pursuant to a loan agreement
dated April 13, 1995, as amended on November 29, 1995 between the Company and
Apotex, Apotex agreed to make loans to the Company (see Note G).
NOTE D - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
[1] Inventories:
Inventories are stated at the lower of cost (first-in, first-out) or
market and subsequent to June 30, 1996 at estimated liquidation value.
[2] Depreciation and amortization:
Property and equipment were depreciated straight-line over their estimated
useful lives which are from three to seven years fixed assets of AVP were
written down to liquidation value as of December 31, 1995.
[3] Revenue recognition:
The Company recognized revenue at the time it shipped its product and it
provided for returns and allowances based upon actual allowances and
trends.
[4] Per share data:
Per share data is based upon the weighted average number of common shares
and equivalents outstanding. The dilutive effect, if any, of outstanding
options and warrants is computed using the "treasury stock" method.
F-11
GEN/RX, INC.
Notes to Financial Statements
December 31, 1996 and 1995
NOTE D - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
[5] Concentration of credit risk:
The Company is subject to credit risk from trade receivables. The Company
marketed its products primarily to domestic wholesalers, distributors and
hospitals. The risk associated with this concentration was believed by the
Company to be limited due to the number of distributors, wholesalers, and
hospitals, their geographic dispersion and the performance of certain
credit evaluation procedures (see Note E). Collateral was generally not
required.
[6] Estimates:
Preparation of these financial statements in conformity with generally
accepted accounting principles requires the use of management's estimates.
NOTE E - MAJOR CUSTOMERS
Two of the Company's customers accounted for approximately 26% and 16% of net
sales in 1995.
NOTE F - INVENTORIES
Inventories relating to discontinued operations at December 31, 1995 consisted
of finished goods. During 1995, the Company took charges aggregating $600,000
for the write-off of short-dated inventories.
NOTE G - NOTES PAYABLE - APOTEX
On January 2, 1996, Apotex, the majority shareholder and primary creditor of the
Company, accelerated approximately $3,500,000 of the outstanding indebtedness of
the Company in favor of Apotex. The Company had failed to pay Apotex
approximately $1,000,000 of indebtedness when it was due on December 22, and, as
a result, after a 10-day grace period, the Company's failure to pay that amount
constituted an Event of Default under the existing lending arrangements between
the Company, as borrower, and Apotex.
The Company and Apotex had entered into these lending arrangements under a loan
agreement dated April 13, 1995 (the "Loan Agreement"). At that date, Apotex
agreed to lend to the Company $500,000 in the form of a term loan and up to
$2,000,000 in the form of a revolving loan. Both loans were evidenced by
promissory notes and would have matured April 13, 1998. The Company has borrowed
the entire line of credit, and the aggregate indebtedness of $2,500,000 is
outstanding. These loans bore interest at the rate of 1% over prime. Interest
was payable on the first business day of each March, June, September and
December, and the Company failed to pay certain accrued and unpaid interest when
due.
The Company's repayment of these amounts was collateralized by all of the assets
of the Company, including AVP's plant in Fort Collins, Colorado. As additional
consideration for the loans, the Company had issued in favor of Apotex, warrants
to purchase the Company's common stock at a purchase price of $1 per share at
the rate of one share for each dollar of loan advanced. The warrants were
exercisable for a period of three years.
F-12
GEN/RX, INC.
Notes to Financial Statements
December 31, 1996 and 1995
NOTE G - NOTES PAYABLE - APOTEX (CONTINUED)
On November 29, 1995, the Company entered into an agreement with Apotex to amend
the Loan Agreement. As amended, the Loan Agreement permitted Apotex, in its
discretion, to advance sums in excess of the $2,500,000 original loan amount,
that were due December 22, 1995, but otherwise were treated as if they had been
advanced pursuant to the Loan Agreement. The Company requested additional
advances and Apotex advanced the Company approximately $325,000 through December
31, 1995. The Company also agreed that failure to repay the amounts when due
would constitute a default under the Loan Agreement. The Company also issued to
Apotex a warrant to purchase an additional 813,783 shares of the Company's
common stock, par value $.004 per share, at an exercise price of $.75 per share
in connection with the amendment. The warrants had a term of three years.
At December 31, 1995, the Company was indebted to Apotex for an aggregate of
$3,563,000 including accounts payable converted to notes pursuant to the
amendment of the loan agreement of $447,000. The Company received additional
advances from Apotex aggregating $862,000 in 1996. The Company's defaults
constituted events of default under the Loan Agreement and Apotex USA
accelerated the entire amount of indebtedness of the Company and its
subsidiaries, which are jointly and severally liable for the debt, by a letter
dated January 2, 1996, which required the Company to turn over to Apotex all of
the collateral on January 5, 1996.
Apotex sought and received the appointment of a receiver for AVP's plant in a
proceeding in Larimer County, Colorado, on January 4, 1996. The order permitted
the receiver to exercise control over AVP's bank accounts, accounts receivable
and inventory (see Note A). As a result of the November 29 letter amendment to
the Loan Agreement and the appointment of a receiver, AVP stopped receiving any
cash proceeds.
Interest expense during 1995 aggregated $1,069,000 including imputed interest of
$915,000 assigned to the value of warrants issued in connection with the merger
and Loan Agreement, as amended with Apotex.
NOTE H - CAPITAL DEFICIT
[1] Warrants:
In connection with the Merger (see Note C) and pursuant to a Loan
Agreement dated April 13, 1995, as amended November 29, 1995; (see Note G)
as additional consideration for the loans, the Company was required to
issue Apotex warrants to purchase shares of the Company's common stock at
the rate of one share for each dollar of loan advanced. Under the terms of
the agreement, Apotex received 2,500,000 warrants exercisable at $1.00 per
share; 813,783 warrants exercisable at $.75 per share and as of December
31, 1995, 498,032 warrants exercisable at $.75 per share in 1996.
Also in connection with the Merger, the Company issued 270,000 warrants to
certain employees and consultants to Apotex, exercisable at $1.50 per
share of common stock. All of the warrants had a term of three years.
F-13
GEN/RX, INC.
Notes to Financial Statements
December 31, 1996 and 1995
NOTE H - CAPITAL DEFICIT (CONTINUED)
[2] Stock options:
The following is a summary of stock option activity during the period July
1, 1994 (AUSA's inception) through December 31, 1994 and the year ended in
1995.
1995 1994
--------------------------- ---------------------------
Price Per Price Per
Share Share Share Share
--------- -------------- ----------- -------------
Outstanding at beginning of period 885,160 $.75 to $2.00 885,160 $.75 to $2.00
Granted 161,500 $.97 to $1.88
Exercised
Canceled (352,000) $.75 to $2.00
---------
Outstanding at end of period 694,660 $.75 to $2.00 885,160 $.75 to $2.00
========= =========
The Company's Incentive Stock Option Plan provided that options may be
granted to employees of the Company for the purchase of up to 300,000
shares of the Company's common stock.
In addition, the Company had options outstanding to purchase 259,500
shares at prices ranging from $.75 to $1.00 per share not pursuant to any
plan.
Options for 412,860 shares were exercisable at December 31, 1995 at prices
ranging from $.75 to $2.00 per share.
NOTE I - INCOME TAXES
In accordance with the relevant provisions of the Internal Revenue Code, the
change of ownership of the Company which occurred in 1996 (see Note C) curtails
in all material respects the ability of the Company to carry forward previously
generated net operating losses.
NOTE J - RELATED PARTY TRANSACTIONS
The Company utilized the service of certain employees of Apotex in the areas of
product development, quality assurance, regulatory affairs, management
information systems, purchasing and other clerical work. As compensation for
these services, AUSA was charged by Apotex for its allocated portion of the
salary and related benefits of these individuals. The costs incurred for these
services for the year ended December 31, 1995 was $352,000. In addition, AUSA
was charged by Apotex for a portion of the occupancy costs incurred. The costs
incurred for these services for the year ended December 31, 1995 was $65,000.
In addition, the Company occupied office space as a subtenant of Apotex although
no formal agreement existed. The Company's monthly rent (paid directly to the
landlord) was equivalent to the rent provided in the lease agreement between
Apotex and the landlord. Rent expense for 1995 was approximately $110,000.
F-14
EXHIBIT INDEX
2.5 Amended and Restated Master Agreement dated April 13, 1995. (Filed as
Exhibit 2.5 to the Company's Annual Report on Form 10-K, as amended, for
the fiscal year ended December 31, 1995.)
2.7 Plan and Agreement of Merger dated April 13, 1995. (Filed as Exhibit 2.7
to the Company's Annual Report on Form 10-K, as amended, for the fiscal
year ended December 31, 1995.)
2.25 Verified Complaint for Appointment of Receiver in Case No. 96CV3 Apotex
USA Inc. v. American Veterinary Products Inc. (Filed as Exhibit 2.25 to
the Company's Annual Report on Form 10-K, as amended, for the fiscal year
ended December 31, 1995.)
2.27 Order Appointing Receiver in Case No. 96CV3 Apotex USA Inc. v. American
Veterinary Products Inc. (Filed as Exhibit 2.27 to the Company's Annual
Report on Form 10-K, as amended, for the fiscal year ended December 31,
1995.)
2.28 First Amended Complaint in Case No. 96CV3 Apotex USA Inc. v. American
Veterinary Products Inc. and 1st Choice Bank.
2.29 1st Choice Bank's Answer, Counterclaim and Amended Cross Claim in Response
to First Amended Complaint in Case No. 96CV3 Apotex USA Inc. v. American
Veterinary Products Inc. and 1st Choice Bank.
2.30 Stipulation Authorizing Sales of Assets dated June 7, 1996 by Receiver,
Apotex USA, Inc. and 1st Choice Bank and Order approving Stipulation dated
June 7, 1996 in Case No. 96CV3 Apotex USA Inc. v. American Veterinary
Products Inc. and 1st Choice Bank.
2.31 Order Regarding Payment of Certain Expenses in Case No. 96CV3 Apotex USA
Inc. v. American Veterinary Products Inc. and 1st Choice Bank.
2.32 Final Report of Receiver in Case No. 96CV3 Apotex USA Inc. v. American
Veterinary Products Inc. and 1st Choice Bank.
2.33 Order dispersing funds and dismissing all claims between Apotex and First
Choice in Case No. 96CV3 Apotex USA Inc. v. American Veterinary Products
Inc. and 1st Choice Bank and attaching Settlement Agreement.
10.2 Separation and Release Agreement dated as of November 6, 1996 among Jack
Schramm and Apotex USA Inc., Gen/Rx, Inc. and Apotex USA Injectables, Inc.
(f/k/a AUSA, Inc.).
10.3 Addendum No. 1 dated as of April 21, 1997 to Separation and Release
Agreement dated as of November 6, 1996 among Jack Schramm and Apotex USA
Inc., Gen/Rx, Inc. and Apotex USA Injectables, Inc. (f/k/a AUSA, Inc.).
16 Letter regarding change in accountants. (Filed as an exhibit to the
Company's Current Report on Form 8-K dated July 10, 1995.)
99.1 Certification